Senomorphics (also known as senostatics) are pharmacological agents that suppress the harmful effects of cellular senescence without necessarily eliminating senescent cells. This distinguishes them from senolytics, which actively kill senescent cells. Senomorphics work by inhibiting the senescence-associated secretory phenotype (SASP), which is the primary mechanism through which senescent cells contribute to chronic inflammation and tissue dysfunction.
The therapeutic potential of senomorphics in neurodegenerative diseases has gained significant attention because:
- They can be administered chronically without the risks associated with cell depletion
- They target the inflammatory pathway that drives neurodegeneration
- They preserve the cell cycle arrest benefits of senescence (tumor suppression)
- They may be more suitable for age-related diseases requiring long-term treatment
¶ Definition and Characteristics
Cellular senescence is a state of irreversible cell cycle arrest that cells enter in response to various stresses:
- DNA damage: Telomere shortening, double-strand breaks, oxidative lesions
- Oncogenic stress: Activation of Ras, BRAF, or other oncogenes
- Replication stress: Exhaustion of replicative capacity (replicative senescence)
- Epigenetic changes: Chromatin remodeling, DNA methylation changes
- Mitochondrial dysfunction: Accumulation of damaged mitochondria
Senescent cells exhibit distinctive characteristics:
- Cellular morphology: Enlarged cell size, flattened morphology, increased granularity
- Growth arrest: Irreversible exit from the cell cycle
- Metabolic changes: Increased autophagy, altered mitochondria
- Chromatin remodeling: Senescence-associated heterochromatin foci (SAHF)
- Secretory phenotype: SASP production
The senescence-associated secretory phenotype is a complex mixture of factors secreted by senescent cells:
| Category |
Factors |
Effect in Neurodegeneration |
| Pro-inflammatory cytokines |
IL-1β, IL-6, IL-8, TNF-α |
Chronic neuroinflammation, microglial activation |
| Chemokines |
CCL2, CCL5, CXCL1, CXCL8 |
Immune cell recruitment, neuroinflammation spread |
| Growth factors |
VEGF, PDGF, TGF-β |
Altered angiogenesis, fibrotic changes |
| Proteases |
MMP-1, MMP-3, MMP-9 |
Extracellular matrix degradation, BBB disruption |
| Coagulation factors |
PAI-1, tPA |
Altered blood clotting |
| Reactive oxygen species |
Superoxide, hydrogen peroxide |
Oxidative stress, neuronal damage |
| ATP/Adenosine |
Extracellular ATP |
P2X/P2Y receptor activation, inflammasome activation |
The SASP is regulated by several key signaling pathways:
flowchart TD
A["DNA Damage/Stress"] --> B["p53 Activation"]
A --> C["ATM/ATR Kinases"]
B --> D["p21 CIP1 upregulation"]
C --> E["NF-κB Activation"]
D --> F["Cell Cycle Arrest"]
E --> G["SASP Transcription"]
E --> H["C/EBPβ Activation"]
G --> I["IL-6, IL-8, TNF-α"]
H --> I
G --> J["MMPs, Chemokines"]
I --> K["Chronic Inflammation"]
J --> L["Matrix Degradation"]
K --> M["Neurodegeneration"]
L --> M
In the central nervous system, SASP from various cell types contributes to neurodegeneration:
- Senescent neurons: Direct secretion of neurotoxic factors
- Senescent astrocytes: Impaired support functions, increased inflammation
- Senescent microglia: Chronic pro-inflammatory state, inefficient phagocytosis
- Senescent oligodendrocyte precursors: Failed remyelination
- Senescent endothelial cells: Blood-brain barrier dysfunction
| Feature |
Senolytics |
Senomorphics |
| Mechanism |
Kill senescent cells |
Suppress SASP/inflammation |
| Target |
Anti-apoptotic pathways |
SASP signaling pathways |
| Effect |
Reduce cell number |
Reduce harmful secretions |
| Advantage |
Complete removal |
Preserve cell cycle arrest |
| Risk |
May disrupt tissue architecture |
May mask underlying issues |
| Dosing |
Intermittent |
Often chronic |
| Examples |
Dasatinib+quercetin, Navitoclax |
Rapamycin, Rapamycin analogs |
Senolytic approach:
- Better for conditions where senescent cell burden is very high
- Useful when cell clearance is beneficial (e.g., fibrosis)
- May be more effective for short-term intervention
Senomorphic approach:
- Better for chronic age-related diseases requiring long-term treatment
- Preserves tumor-suppressive benefits of senescence
- Lower risk of unintended tissue damage
- More suitable for neurodegenerative diseases
The mTOR (mammalian target of rapamycin) pathway is a master regulator of cellular metabolism and SASP production:
- Rapamycin: Inhibits mTORC1, reduces SASP without affecting cell cycle arrest
- Everolimus: Similar mechanism, used in transplant and oncology
- Mechanism: Blocks SASP translation without affecting transcription
- Evidence in neurodegeneration: mTOR inhibition promotes autophagy, reduces tau pathology
NF-κB is a central transcription factor for inflammatory genes:
- Inhibitors: BAY 11-7082, IKK inhibitors
- Natural compounds: Curcumin, resveratrol
- Mechanism: Prevents IκB degradation, blocks NF-κB nuclear translocation
- Effect: Reduces SASP cytokines, particularly IL-6, IL-8
The p53 tumor suppressor regulates both senescence and SASP:
- Pifithrin-α: Inhibits p53 transcriptional activity
- Nutlin-3: MDM2 antagonist, stabilizes p53
- Dual role: p53 activation can both induce and suppress SASP depending on context
FOXO4 regulates senescence and SASP through p53 interactions:
- FOXO4-p53 interaction: sequesters p53 in nucleus
- FOXO4 inhibitors: Disrupt p53-FOXO4 interaction
- Effect: Promotes p53 activity, can induce senescent cell apoptosis
Heat shock protein 90 stabilizes many pro-survival and SASP proteins:
- Inhibitors: Geldanamycin, 17-DMAG, Ganetespib
- Targets: Client proteins including IKK, AKT, STAT3
- Effect: Reduces SASP, sensitizes to apoptosis
While primarily targets for senolytics, Bcl-2 family proteins also regulate SASP:
- Bcl-2, Bcl-xL, Mcl-1: Anti-apoptotic, also affect SASP
- BH3 mimetics: Can have senomorphic effects
¶ Senomorphic Drug Candidates
¶ Rapamycin and Analogs
Mechanism:
- mTORC1 inhibition
- Blocks SASP at translational level
- Enhances autophagy
Evidence in neurodegeneration:
- Extends lifespan in mouse models
- Reduces amyloid-β and tau pathology
- Improves cognitive function in AD models
- Reduces neuroinflammation in PD models
Clinical status:
- NCT04641495: Rapamycin for AD (completed)
- Multiple trials in related conditions
Mechanism:
- AMPK activation
- mTOR inhibition
- Reduced NF-κB signaling
- senolytic effects at high doses
Evidence in neurodegeneration:
- Reduced dementia risk in diabetic patients
- Improves biomarkers in AD
- Reduces neuroinflammation
Clinical status:
- NCT04098628: Metformin for MCI/AD
- Multiple ongoing trials
While primarily senolytic, D+Q also has senomorphic effects:
- Dasatinib: Reduces SASP through Src inhibition
- Quercetin: Antioxidant, anti-inflammatory
- Combined: Both senolytic and senomorphic
Mechanism:
- mTOR inhibition
- Senolytic and senomorphic
- Antioxidant effects
Evidence:
- Reduces SASP in vitro
- Improves cognitive function in aged mice
Several natural compounds have senomorphic properties:
- Resveratrol: SIRT1 activator, NF-κB inhibitor
- Curcumin: NF-κB inhibitor, antioxidant
- Quercetin: Multiple mechanisms
- Epigallocatechin gallate (EGCG): mTOR inhibition
- Sulforaphane: Nrf2 activation
Senescent cells accumulate in AD brain and contribute to:
- Amyloid pathology: SASP may accelerate amyloid-β production
- Tau pathology: Inflammatory signaling promotes tau phosphorylation
- Neuroinflammation: Chronic microglial activation
- Neuronal loss: Direct toxic effects of SASP
Evidence:
- Senescent glial cells in AD brain tissue
- SASP factors detected in CSF of AD patients
- Mouse models show benefits from senolytic/senomorphic treatment
In PD, senescence contributes to:
- Dopaminergic neuron loss: SASP-mediated toxicity
- α-Synuclein pathology: Inflammation promotes aggregation
- Microglial activation: Chronic neuroinflammation
- Gut-brain axis: Senescent cells in enteric nervous system
Evidence:
- Senescent cells in substantia nigra of PD patients
- α-Synuclein transmission enhanced by SASP
- D+Q improves outcomes in PD models
Senescence in ALS:
- Motor neuron environment: Senescent astrocytes toxic to neurons
- Inflammation: SASP drives disease progression
- Muscle: Senescent muscle cells contribute to pathology
Evidence:
- Senescent astrocytes in ALS models
- Reduced disease progression with senolytic treatment
Senescence contributes to:
- Tau pathology: Inflammatory signaling
- Neuroinflammation: Similar to AD
- TDP-43 pathology: May be accelerated by SASP
- Neuronal senescence: Early occurrence in HD
- SASP: Contributes to striatal degeneration
- Evidence: Senolytic treatment improves outcomes in HD models
| Trial ID |
Compound |
Condition |
Phase |
| NCT04641495 |
Rapamycin |
Alzheimer's disease |
Phase 2 |
| NCT04098628 |
Metformin |
MCI/AD |
Phase 3 |
| NCT03430037 |
D+Q |
Alzheimer's disease |
Phase 1 |
| NCT04063124 |
D+Q |
Parkinson's disease |
Phase 1 |
| NCT04129941 |
Dasatinib |
ALS |
Phase 1 |
| Trial ID |
Compound |
Condition |
Outcome |
| NCT02874989 |
D+Q |
Pulmonary fibrosis |
Reduced senescent cells |
| NCT02931318 |
D+Q |
Diabetic kidney disease |
Reduced SASP markers |
The SASP is a primary driver of chronic neuroinflammation:
Cellular senescence is a hallmark of aging:
Senomorphics often enhance autophagy:
Senescence and mitochondrial dysfunction are linked:
May interact with senescence:
- Chronic dosing: Suitable for long-term age-related treatment
- Preserved senescence: Maintains tumor-suppressive benefits
- Lower risk: Less likely to cause tissue damage
- Combination potential: Can combine with senolytics
- Multiple targets: Multiple pathways can be addressed
- Incomplete mechanism suppression: May not fully address senescence burden
- Systemic effects: Broad anti-inflammatory effects
- Dosing: Finding optimal chronic dose
- Biomarkers: Need better SASP biomarkers
- Blood-brain barrier: Many compounds may not cross effectively
Emerging strategies combine senomorphics with:
- Senolytics: Periodic clearance with chronic suppression
- Anti-inflammatory drugs: Enhanced effect
- Autophagy enhancers: Complementary mechanisms
- Targeted delivery: Better CNS penetration
- SASP factor measurement in blood/CSF
- Imaging of senescent cells
- Genetic markers of senescence
- Specific mTORC2 inhibitors
- New-generation NF-κB inhibitors
- SASP-targeted antibodies
- Microbiome-modulating senomorphics
- Nanoparticle delivery to brain
- Prodrugs with CNS targeting
- Gene therapy approaches